Celldex Therapeutics (CLDX) Accumulated Depreciation (2016 - 2024)
Historic Accumulated Depreciation for Celldex Therapeutics (CLDX) over the last 14 years, with Q4 2024 value amounting to $23.5 million.
- Celldex Therapeutics' Accumulated Depreciation rose 482.02% to $23.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $23.5 million, marking a year-over-year increase of 482.02%. This contributed to the annual value of $23.5 million for FY2024, which is 482.02% up from last year.
- Latest data reveals that Celldex Therapeutics reported Accumulated Depreciation of $23.5 million as of Q4 2024, which was up 482.02% from $22.4 million recorded in Q4 2023.
- Celldex Therapeutics' Accumulated Depreciation's 5-year high stood at $23.5 million during Q4 2024, with a 5-year trough of $21.1 million in Q4 2021.
- Its 5-year average for Accumulated Depreciation is $22.0 million, with a median of $21.6 million in 2022.
- As far as peak fluctuations go, Celldex Therapeutics' Accumulated Depreciation tumbled by 2522.97% in 2020, and later soared by 482.02% in 2024.
- Quarter analysis of 5 years shows Celldex Therapeutics' Accumulated Depreciation stood at $21.2 million in 2020, then dropped by 0.52% to $21.1 million in 2021, then rose by 2.37% to $21.6 million in 2022, then increased by 3.51% to $22.4 million in 2023, then grew by 4.82% to $23.5 million in 2024.
- Its Accumulated Depreciation was $23.5 million in Q4 2024, compared to $22.4 million in Q4 2023 and $21.6 million in Q4 2022.